Lipodystrophic Laminopathies: From Dunnigan Disease to Progeroid Syndromes
Loading...
Identifiers
Publication date
Advisors
Tutors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Abstract
Lipodystrophic laminopathies are a group of ultra-rare disorders characterised by the presence of pathogenic variants in the same gene (LMNA) and other related genes, along with an impaired adipose tissue pattern and other features that are specific of each of these disorders. The most fascinating traits include their complex genotype-phenotype associations and clinical heterogeneity, ranging from Dunnigan disease, in which the most relevant feature is precisely adipose tissue dysfunction and lipodystrophy, to the other laminopathies affecting adipose tissue, which are also characterised by the presence of signs of premature ageing (Hutchinson Gilford-progeria syndrome, LMNA-atypical progeroid syndrome, mandibuloacral dysplasia types A and B, Nestor-Guillermo progeria syndrome, LMNA-associated cardiocutaneous progeria). This raises several questions when it comes to understanding how variants in the same gene can lead to similar adipose tissue disturbances and, at the same time, to such heterogeneous phenotypes and variable degrees of metabolic abnormalities. The present review aims to gather the molecular basis of adipose tissue impairment in lipodystrophic laminopathies, their main clinical aspects and recent therapeutic strategies. In addition, it also summarises the key aspects for their differential diagnosis.
Description
Bibliographic citation
Díaz-López, E.J.; Sánchez-Iglesias, S.; Castro, A.I.; Cobelo-Gómez, S.; Prado-Moraña, T.; Araújo-Vilar, D.; Fernandez-Pombo, A. Lipodystrophic Laminopathies: From Dunnigan Disease to Progeroid Syndromes. Int. J. Mol. Sci. 2024, 25, 9324. https://doi.org/10.3390/ ijms25179324
Relation
Has part
Has version
Is based on
Is part of
Is referenced by
Is version of
Requires
Sponsors
This study was supported by the Instituto de Salud Carlos III (grant PI22/00514) and co-funded by the European Union and an intramural grant from the Xunta de Galicia, ED431B 2020/37. A.F.-P. is funded by a Juan Rodes research contract (JR23/00042) from the Instituto de Salud Carlos III (ISCIII), co-financed by the ERDF. S.S.-I. was awarded a Research Fellowship by the Asociación Española de Familiares y Afectados de Lipodistrofias (AELIP).
Rights
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license








